Ireland
--:--IST
Recruiting Phase 3

Effect of Preventive Analgesia by Injection of a Local Anesthetic Before Vaginal Incision for Hysterectomy by vNOTES Approach

NCT05969457 · tracked via the Priya Life Science France tracker
Phase
Phase 3
Started
2025-09-16
Last updated
2026-06-08

Condition(s) studied

Hysterotomy; Affecting Fetus

Investigational drug(s) / intervention(s)

NaropeinequestionnairesPlacebo

Naropeine: Local anesthesia with injection of Ropivacaine (20mL of ropivacaine 7.5 mg/mL, i.e. 150mg)

questionnaires: Numerical Rating scale Questionnaire FSFI Qustionnaire SF12 Questionnaire DN4

Placebo: Injection of 20 mL of NaCl

Study summary

The research procedure is the injection of 20 mL of Ropivacaine solution (vs. saline) to create a paracervical block at the beginning of surgery, while the patient is already under general anesthesia.

This injection will take place 3 minutes before the vaginal incision, via 4 injection points. Injections are made 3 mm deep into the vaginal cul de sac.

Randomization takes place before surgery by vNOTES:

* Experienced group: Local anesthesia with injection of Ropivacaine (20mL of ropivacaine 7.5 mg/mL, i.e. 150mg) and general anesthesia
* Control group: Injection of 20mL of placebo (saline) and general anesthesia

In both groups, systematic intraoperative and postoperative analgesia will be identical.

Eligibility

Sex
FEMALE
Min age
18 Years
Max age
70 Years
Healthy volunteers
No
Inclusion Criteria: * Adult patients aged 18 to 70 inclusive * Patient scheduled for vNOTES surgery for total hysterectomy for benign pathology, whether or not associated with an adnexal procedure (unilateral or bilateral salpingectomy or adnexectomy (for cysts smaller than 6 cm)). * Person having read and understood the information letter and signed the consent form * Person affiliated to a social security scheme Exclusion Criteria: * Suspicion of malignant pathology * History of rectal surgery * History of pelvic inflammatory disease * Suspicion of recto-vaginal endometriosis * Virginity * Contraindication to NAROPEINE 7.5 mg/mL, solution for injection in ampoule * Contraindication to PROAMP SODIUM CHLORIDE 0.9%, solution for injection * Patients on a low-salt diet * History of more than 2 caesarean sections * Estimated uterine size \> 700 g according to the following formula y = 0.35x + 107 (x = a × b × c), based on measurements taken on preoperative imaging (MRI or ultrasound). a=longitudinal diameter, b=sagital diameter, c=transverse diameter.3 * BMI \> 35 * Contraindication to analgesic molecules in intraoperative and postoperative protocols.

Primary outcome measure(s)

  • pain after surgery — 4hours after surgery
    Pain will be assessed by the post-operative hospital nurse using a numerical rating scale (NRS) NRS score from 1 to 10 -\> 10 correspoding to the worst pain

Trial sites (2)

FacilityCityRegionStatus
Gh Le Havre Le Havre France Recruiting
Chu Rouen Rouen France Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT05969457 on ClinicalTrials.gov ↗ ← All trials in France